Inovio Pharmaceuticals Inc

NASDAQ:INO   3:59:58 PM EDT
10.46
-0.49 (-4.47%)
4:02:53 PM EDT: $10.45 -0.01 (-0.10%)
Products

Inovio Reports FDA Partial Clinical Hold For Planned Phase 2 / 3 Trial Of Covid-19 Vaccine Candidate Ino-4800

Published: 09/28/2020 11:10 GMT
Inovio Pharmaceuticals Inc (INO) - Inovio Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of Covid-19 Vaccine Candidate Ino-4800.
Inovio Pharma - Partial Clinical Hold is Not Due to Occurrence of Any Adverse Events Related to Inovio's Ongoing Expanded Phase 1 Study of Ino-4800.
Inovio Pharmaceuticals Inc - Actively Working to Address FDA's Questions and Plans to Respond in October.
Inovio Pharma - Co, Partners Are Continuing to Prepare for a Planned Phase 2/3 Trial of Ino-4800, Following Resolution of FDA's Partial Clinical Hold.
Inovio - FDA Has Additional Questions About Planned Phase 2/3 Trial of Ino-4800, Including Cellectra 2000 Delivery Device to Be Used in Trial.